|
TRI group |
TFI group |
Number of patients [n (%)] |
340(51.56) |
321(48.43) |
Age (years) |
64.5±9.74 |
65.9±12.8 |
Male gender [n (%)] |
264(77.64) |
253(75.7) |
Systemic hypertension [n (%)] |
176(51.76) |
163(50.77) |
Diabetes mellitus [n (%)] |
115(33.82) |
104(32.39) |
Hypercholesterolemia [n (%)] |
100(29.41) |
97(30.21) |
Current smoker [n (%)] |
191(56.17) |
180(56.07) |
Previous MI [n (%)] |
21(6.17) |
19(5.91) |
Location of MI |
|
|
Anterior [n (%)] |
188(55.29) |
171(53.27) |
Inferior or posterior [n (%)] |
152(44.7) |
150(46.72) |
Killip Class |
|
|
I [n (%)] |
215(63.23) |
201(62.61) |
II [n (%)] |
79(23.23) |
73(22.74) |
III or IV [n (%)] |
46(13.52) |
47(14.64) |
Concomitant therapy |
|
|
Aspirin [n (%)] |
335(98.52) |
318(99.06) |
Clopidogrel [n (%)] |
336(98.82) |
319(99.37) |
Beta-blocker [n (%)] |
311(91.47) |
296(92.21) |
ACEI/ARB [n (%)] |
298(87.64) |
274(85.35) |
Statin [n (%)] |
322(94.7) |
299(93.14) |
Values are presented as mean ± standard deviation or n (%).
*Denotes statistical difference (p < 0.05) compared to normal group.
TRI,transradial intervention;TFI,transfemoral intervention; MI, myocardial infarction;
ACEI, angiotensin converting enzyme inhibitor; ARB,angiotensin receptor
blocker |